Author:
Khaledi Mansoor,Sameni Fatemeh,Yahyazade Sheida,Radandish Maedeh,Owlia Parviz,Bagheri Nader,Afkhami Hamed,Mahjoor Mohamad,Esmaelpour Zahra,Kohansal Maryam,Aghaei Farzad
Abstract
Recent evidence proposed that the severity of the coronavirus disease 2019 (COVID-19) in patients is a consequence of cytokine storm, characterized by increased IL-1β, IL-6, IL-18, TNF-α, and IFN-γ. Hence, managing the cytokine storm by drugs has been suggested for the treatment of patients with severe COVID-19. Several of the proinflammatory cytokines involved in the pathogenesis of COVID-19 infection recruit a distinct intracellular signaling pathway mediated by JAKs. Consequently, JAK inhibitors, including baricitinib, pacritinib, ruxolitinib, and tofacitinib, may represent an effective therapeutic strategy for controlling the JAK to treat COVID-19. This study indicates the mechanism of cytokine storm and JAK/STAT pathway in COVID-19 as well as the medications used for JAK/STAT inhibitors.
Reference192 articles.
1. A review on phylogenetic assessment and cytopathogenesis of filoviruses, retroviruses, and coronaviruses transmitted from bat to human;Khaledi,2021
2. Etymologia: coronavirus;Henry;Emerg Infect Dis.,2020
3. An overview on COVID-19: reality and expectation;Hamed;Bull Natl Res Cent.,2020
4. COVID-19 outbreak: an overview;Ciotti;Chemotherapy.,2019
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献